Louisiana State Employees Retirement System Purchases 200 Shares of United Therapeutics Corporation $UTHR

Louisiana State Employees Retirement System boosted its position in United Therapeutics Corporation (NASDAQ:UTHR) by 1.6% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,700 shares of the biotechnology company’s stock after acquiring an additional 200 shares during the period. Louisiana State Employees Retirement System’s holdings in United Therapeutics were worth $3,649,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in UTHR. UMB Bank n.a. grew its holdings in United Therapeutics by 17.1% in the 1st quarter. UMB Bank n.a. now owns 1,289 shares of the biotechnology company’s stock worth $397,000 after acquiring an additional 188 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in United Therapeutics by 20.3% in the 1st quarter. Farther Finance Advisors LLC now owns 456 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 77 shares during the last quarter. SG Americas Securities LLC grew its holdings in United Therapeutics by 210.9% in the 1st quarter. SG Americas Securities LLC now owns 10,085 shares of the biotechnology company’s stock worth $3,109,000 after acquiring an additional 6,841 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in United Therapeutics by 18.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 65,405 shares of the biotechnology company’s stock worth $20,162,000 after acquiring an additional 10,290 shares during the last quarter. Finally, Fifth Third Bancorp grew its holdings in United Therapeutics by 22.7% in the 1st quarter. Fifth Third Bancorp now owns 487 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 90 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $448.93 on Thursday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $459.48. The stock has a market cap of $20.25 billion, a P/E ratio of 17.52, a price-to-earnings-growth ratio of 6.96 and a beta of 0.66. The firm has a 50-day moving average of $365.94 and a 200 day moving average of $321.87.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. During the same period last year, the business earned $5.85 earnings per share. The company’s revenue was up 11.7% on a year-over-year basis. Research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on UTHR shares. Bank of America raised their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of United Therapeutics in a research report on Wednesday. Jefferies Financial Group raised their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Finally, Royal Bank Of Canada started coverage on shares of United Therapeutics in a research report on Friday, September 26th. They issued an “outperform” rating and a $569.00 target price for the company. Ten research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $449.57.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at $11,356,133.75. This trade represents a 23.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 257,935 shares of company stock valued at $103,782,672. 10.30% of the stock is currently owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.